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Abstract
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-rafmurine sarcoma viral oncogene homolog B1
(BRAF) that causes the steady-state activation of extracellular signal–regulated kinase (ERK). We sought to investigate
the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects
of BRAF in melanoma. EXPERIMENTAL DESIGN: Well-characterized melanoma cell lines, including several with ac-
quireddrug resistance,wereexposed toPLX4032.Growth inhibition, phosphosignaling, cell cycle, apoptosis, andgene
expression analyses were performed before and after exposure to drug. RESULTS: Using a growth-adjusted inhibitory
concentration of 50% cutoff of 1 μM, 13 of 35 cell lines were sensitive to PLX4032, 16 resistant, and 6 intermediate
(37%, 46%, and 17% respectively). PLX4032 caused growth inhibition, G0/G1 arrest, and restored apoptosis in the
sensitive cell lines. A BRAF mutation predicted for but did not guarantee a response, whereas a neuroblastoma RAS
viral oncogene homolog mutation or wild-type BRAF conferred resistance. Cells with concurrent BRAF mutations
and melanocortin 1 receptor germ line variants and/or a more differentiated melanocyte genotype had a preferential
response. Acquired PLX4032 resistance reestablishes ERK signaling, promotes a nonmelanocytic genotype, and
is associated with an increase in the gene expression of certain metallothioneins and mediators of angiogenesis.
CONCLUSIONS: PLX4032 has robust activity in BRAF mutated melanoma. The preclinical use of this molecule iden-
tifies criteria for its proper clinical application, describes patterns of and reasons for response/resistance, and affords
insight into the role of a BRAF mutation in melanoma.
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Introduction
Malignant melanoma (MM) has long been considered a single histo-
logic entity with heterogeneous clinical phenotypes. Evaluations of
sun damage, mutations (v-raf murine sarcoma viral oncogene homo-
log B1 [BRAF], neuroblastoma RAS viral (v-ras) oncogene homolog
[NRAS], and v-kitHardy-Zuckerman 4 feline sarcoma viral oncogene
homolog [CKIT]), and gene polymorphisms (melanocortin 1 receptor
[MC1R]) indicate that melanoma is actually composed of distinct
clinical and molecular entities driven by various oncogenic events
[1–3]. The identification of these molecular alterations permits the
development of targeted therapies tailored to the specific pathway le-
sions of individual tumors. The presence of these aberrations, how-
ever, has not necessarily predicted for or conferred expected clinical
responses [4,5]. This emphasizes the diverse nature of melanoma,
questions its dependence on single “oncogenic” events, demonstrates
the complexity inherent to and of targeting molecular pathways, and
highlights the need to identify the proper application of novel inhibi-
tors through preclinical models.
The mitogen-activated protein kinase (MAPK) pathway is impli-
cated in the pathogenesis and propagation of melanoma because of
mutations in transmembrane receptor tyrosine kinases (RTKs) (CKIT
3%-5%), membrane-associated guanine nucleotide binding proteins
(NRAS 15%-20%), and cytoplasmic serine/threonine kinases (BRAF
60%-75%). Collectively, the effect of these aberrant signaling media-
tors is the steady-state activation of extracellular signal–regulated kinase
(ERK) observed in 90% of melanomas [6,7]. Regardless of the causa-
tive upstream event, ERK overexpression promotes the differentiation,
malignant transformation, proliferation, and survival of MM [7]. Spe-
cific to ERK activation in BRAF mutated melanoma, as opposed to
RTK mediated ERK activation, is its resistance to negative feedback
inhibition from the dual specific phosphatases (DUSP) and sprouty
family (SPRY) of RAF binding proteins [8]. Also, the presence of a
BRAFmutation (BRAFm) seems to evoke downstream transcriptional ac-
tivity of ERK throughMYC, FOS-like antigen 1 (FOSL1), and the ETS
family of transcription factors [8]. Activation of the phosphoinositide-
3-kinase (PI3K) pathway is documented in more than 70% of MM
[9]. Synergistic activity of BRAF and v-akt murine thymoma viral on-
cogene homolog (AKT) has been implicated in the pathogenesis and
malignant transformation of melanoma [10,11].
In BRAF-mutated melanomas, a simple amino acid transversion
(exon 15, activation loop) confers a 500-fold increase in its kinase
activity [12]. This, along with its role in the pathogenesis and prop-
agation of MM, makes it an attractive clinical target. PLX4032
(RO5185426; Plexxikon/Roche, Berkeley, CA) inhibits oncogenic
BRAF mutated at residue 600 with high affinity (IC50 44 nM) [13].
Early reporting of a phase 1 clinical trial of PLX4032 has yielded prom-
ising results in MM [14,15]. Clinical responses seem to be restricted
to tumors with a BRAFm; however, the presence of a BRAFm did not
unconditionally confer a response. Stratifying patients in the context of
defined pathway lesions is a critical step in applying targeted therapies
and in determining predictors of response. It is feasible to scrutinize the
efficacy of PLX4032 in preclinical models to determine the effects of
BRAF inhibition in melanoma and the molecular role of a BRAFm in
melanogenesis and to gain an understanding as to which patient should
be treated withMAPK pathway inhibitors.We investigated these ques-
tions by evaluating the inhibitory/molecular effects of PLX4032 in a
well-characterized panel of MM cell lines.
Materials and Methods
Cell Lines, Culture, and Reagents
Cell lines are described in Figure 1A. SKMEL2, SKMEL28, and
WM2664 were cultured with Eagle minimal essential medium (Amer-
ican Type Culture Collection [ATCC], Manassas, VA). G361 and
SKMEL3 were cultured with McCoy’s-5A modified medium with
L-glutamine (ATCC). All others were cultured in RPMI-1640 (ATCC).
All media were supplemented with 10% heat-inactivated FBS (Omega
Scientific, Inc, Tarzana, CA) and 1% penicillin and streptomycin (Irvine
Scientific, Santa Ana, CA).
Polymerase Chain Reaction and Sequencing
DNA was extracted with DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA). Exons were amplified by polymerase chain reaction
(HotMaster Taq Polymerase; 5 Prime, Hamburg, Germany). Products
were purified (PCR Purification Kit; Qiagen) and sequenced (BigDye
Terminator Kit, 3730XL Instrument; Applied Biosystems, Inc, Foster
City, CA). Primer sets are shown in the Supplemental Material.
Proliferation Assays
Proliferation assays were performed as previously described [16].
Serial dilutions of PLX4032 started at 10 μM. Growth inhibition/
lethality was calculated as previously described [16] (RAD001
[Selleck Chemicals, Houston, TX] and LY294002 [Sigma-Aldrich,
St Louis, MO]).
Figure 1. Functional activity of PLX4032. (A) Growth inhibition assay ofMMcell lines (n=35) after exposure to PLX4032. The concentration
of drug in micromolars that achieves a growth adjusted inhibitory concentration of 50% (IC50g μM) (x-axis), melanoma cell line (y-axis). SE
is depicted. Table outlines characteristics of the 35 MM cell lines. Order of cell lines corresponds to the growth inhibition chart. Cell lines
are color coordinated based on response (pink—clear sensitivity, orange—intermediate sensitivity, gray—resistant). In parenthesis next to
the cell line: *cellswere purchased fromATCCor^developed from tumor samples at UCLA (University California, Los Angeles), +cell lines
that were included in the complementary RNAmixed reference pool for themicroarray analysis. Lethality = cell death in addition to growth
inhibition. BRAF andNRAS statuswith specific amino acid substitutions;MC1R germ line status/gene polymorphism; R versus r describes
the functional effect of MC1R variant/relation to skin pigmentation [3]. Gene expression groupings: DMG = differentiated melanocyte
group, NPG=neuronal precursor group. PTEN and PI3K status: presence ofMITF amplification as determined by focal in situ hybridization
(>2 genes per chromosome 3 centromeres). (B) Phosphoprotein signaling of MM cell lines throughWestern blot analysis before and after
exposure to PLX4032. Cell lines are listed in order of sensitivity. Composite arrangement of multiple Western blots is depicted by divid-
ing lines. BRAFm cell lines are outlined in a red box; NRASm, blue; and BRAFwt/NRASwt, green. (C) Western blot analysis of two BRAFm
(Malme3MandWM2664) and twoNRASm (M202 andM207)MMcell lines after exposure to increasing concentrations of PLX4032. (D) Cell
cycle and apoptosis assays as done by flow cytometry. Chart depicts percent change in the number of cells in G0/1 (blue bar) and the
number of cells in apoptosis (maroon bar) of the treated cell line versus the untreated control.
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Western Blot
Western blot analysis was performed as previously described [16].
Cells were treated with 3 μM PLX4032 for 30 minutes. Antibodies
(anti-AKT1, anti-AKT2, anti-AKT3, anti-AKT [C67E7], anti-phospho-
p70 S6 kinase [Ser371], anti-p70 S6 kinase, anti–phospho-MAPK/
ERK kinase [MEK1/2; Ser217/221], anti-MEK1/2, anti–phospho-
A-Raf [Ser299], anti–A-Raf, anti–phospho-B-Raf [Ser445], anti-Braf
[55C6], anti–phospho-C-Raf [Ser529], and anti–C-Raf) were purchased
from Cell Signaling Technology, Inc (Danvers, MA).
Cell Cycle and Apoptosis
Cell cycle and apoptosis assays were performed as previously de-
scribed [16]. Cells were treated with 3 μMPLX4032. For the cell cycle
analysis, cells were harvested after 3 days. For the apoptosis assay, cells
were harvested after 5 days.
Acquired PLX4032 Resistance
Cell lines were separated into two T-75 flasks and cultured in par-
allel; one was treated at their growth-adjusted inhibitory concentration
of 50% (IC50g), the other with DMSO. Concentrations of PLX4032
were increased as resistance developed. Cell line identity was con-
firmed by mitochondrial DNA comparative analysis to the highly
variable regions 1/2 of the modified Cambridge sequence. Growth rate
of M14R, M288R, and SKMEL28R was determined as follows: M14R,
M288R, and SKMEL28R were grown in two sets of flasks, one in stan-
dard culture medium, the other in culture medium supplemented with
3 μM of PLX4032. On day 7, cells from each flask were plated in
duplicate in 12-well plates (10,000 cells/2 ml/well). PLX4032 (3 μM)
was added to the medium of cells initially grown in the presence of
PLX4032 (W/PLX4032); of the cells initially grown without PLX4032,
one set was supplemented with the BRAF inhibitor (W/O → W/
PLX4032), the other was continued to be grown in the absence of drug
(W/OPLX4032). Cell counts were performed on days 0, 3, 4, 5, 6, 7, 10,
11, 12, 13, and 14 (Z1 Particle Counter; Beckman Coulter, Brea, CA).
Ras Activation Assay
Ras activation assay was performed as previously described [17].
The cells were cultured to approximately 85% to 90% confluence
and were harvested after being treated with 3 μMPLX4032 or DMSO
for 30 minutes. Equal amounts of cell lysates were used for the activa-
tion assay (Ras Activation Assay Kit; Millipore, Billerica, MA).
Microarray Analyses
Baseline characterization. RNA was extracted, quantified, and hy-
bridized as previously described [16]. A total of 35 melanoma cell lines
were hybridized to Agilent Human 1A-oligo arrayV1 chips (Agilent
Technologies, Santa Clara, CA).Melanoma cell lines used in the mixed
reference complementary RNA pool are listed (Figure 1A).
Before/After PLX4032. Cells were grown to midlog phase and
treated with 3 μM PLX4032 or DMSO for 24 hours. Cell harvesting/
RNA extraction was previously described [16]. Microarray hybridi-
zations were performed using the Agilent Human 4x44K array chip
(Agilent Technologies).
Microarray slides were read as previously described [16]. Rosetta
Resolver analysis of variance (ANOVA) was performed using the
Benjamini–Hochberg false discovery rate multiple test correction.
Two-dimensional cluster analysis was performed using an agglomerate
hierarchical clustering algorithm based on the cosine correlation sim-
ilarity metric.
Results
Mutational Status/Response PLX4032
A panel of 35melanoma cell lines was exposed to PLX4032 through
a 7-day growth inhibition assay. A differential response pattern was
established (Figure 1A). Using an IC50g cutoff of 1 μM as clearly sen-
sitive and 3 μM as resistant, 13 cell lines were sensitive, 16 were resis-
tant, and 6 were intermediate. Mutational analysis revealed that a
V600 BRAFm conferred sensitivity (clear and intermediate) regardless
of zygosity or amino acid substitution (E, D, K). Sensitive cell lines
(clear and intermediate) harbored a BRAFm, whereas only four BRAF
mutated cell lines were resistant. An NRAS mutation (NRASm) or
the absence of either mutation (BRAFwt/NRASwt) conferred resistance
(7/7NRASm and 5/5 BRAFwt/NRASwt resistant). These data show the
specificity of PLX4032 and suggest that its clinical application should
focus on V600 BRAF mutated melanomas regardless of zygosity or
specific amino acid substitution.However, as in the phase 1 clinical trial,
a BRAFm did not necessarily confer a response to treatment [14,15].
Evaluation of MC1R status showed a predilection for MC1R var-
iants (MC1Rv) in the sensitive cell lines but did not supersede the pres-
ence of a BRAFm (Figure 1A). Moreover, 12 of 13 sensitive and 5 of 6
intermediate lines had a MC1Rv. All of these cell lines also had a con-
current BRAFm. Only 4 of 16 resistant cell lines had a MC1Rv. None
of these had a concurrent BRAFm. It has been reported that MC1Rv
are more prevalent in BRAF mutated samples [3,18]. Our data con-
firm this and suggest that melanomas with a MC1Rv may be more
dependent on selective ERK signaling associated with a BRAFm as op-
posed to an aberrant RTKor aNRASm.No correlation was observed in
the BRAFm/MC1Rv cell lines regarding the specific MC1R polymor-
phism or its proposed functional effect (r vs R).
BRAFm cooperates with phosphatase and tensin homolog (PTEN)
loss in MM development [11]. Of 35 cell lines, 7 (20%) had a PTEN
mutation (PTENm) (Figure 1A). PTENm were mutually exclusive
with NRASm as previously reported [19]. Of the seven PTENm sam-
ples, six also had concurrent BRAFm; therefore, a trend was observed
between PTEN status and response to PLX4032. As most of the sen-
sitive cell lines were BRAFm/PTENwt, it is apparent that the BRAFm,
regardless of PTEN status, drives the response to PLX4032. These
data suggest that although up-regulation of the PI3K/AKT/mechanistic
target of rapamycin (mTOR) pathway through PTEN loss may poten-
tiate melanoma formation in BRAF mutated nevi, once established,
an MM sample depends preferentially on aberrant ERK signaling
under the influence of BRAFm. The role of PTEN loss through muta-
tions or epigenetic modifications may become more prominent in the
BRAF mutated samples if ERK signaling is perturbed. The PI3K/AKT
pathway may then regulate the MAPK pathway similar to its activity in
early melanocytogenesis [10].
Phosphosignaling
Western blot analysis was performed before and after exposure to
PLX4032 (Figure 1B). p-ERK was downregulated after treatment in
all BRAF mutated samples including the resistant ones. SKMEL31,
sensitive, was an exception to this. A discrepancy exists in the litera-
ture regarding the BRAF status of SKMEL31 [8,20–23]. In this analy-
sis, SKMEL31 was confirmed through repeated sequencing as having
a heterozygous BRAFm. However, evaluation of its chromatogram
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suggests that it may have an allelic imbalance in which the percentage
of the wild-type allele is increased compared to the mutant [24]. A
decrease in p-ERK was not noted in NRAS mutated or BRAFwt/
NRASwt samples (Figure 1B). Rather, after treatment, these samples
had an initial increase in p-ERK signaling. This was time- (data not
shown) and dose-dependent (Figure 1C ). Evaluation of total and
p-MEK, a direct readout of RAF signaling, mirrored p-ERK signaling
(Figure 1B). This demonstrates that no additional cellular input occurs
in between RAF and ERK signaling and that the evaluation p-ERK
signaling gives an accurate assessment of RAF activity after exposure
to PLX4032. No significant changes were seen in p-AKT in any of
the samples (Figure 1B).
Cell Cycle and Apoptosis
ERK activity in BRAFmutated melanoma cells is capable of driving
cellular proliferation through dysregulation of the cell cycle. Aberrant
MAPK activity can also suppress apoptosis by inactivating proapopto-
tic members of the Bcl-2 family (BH3 and BH1/BH3 domain con-
taining proteins) and by increasing antiapoptotic members (Bcl-2,
Mcl-1, and Bcl-XL). Cell cycle and apoptosis assays were performed
before and after exposure to PLX4032 (Figure 1D). An accumulation
of cells in the G0/G1 phase of the cell cycle was noted in the majority of
sensitive but not resistant lines. Evaluation of apoptosis showed that
PLX4032 caused an increase in apoptosis in the majority of the sensi-
tive as opposed to the resistant samples. Together, these data show that
inhibiting the mutated BRAF kinase can abrogate the proliferative ef-
fects and survival advantage of aberrant ERK signaling.
Baseline Gene Expression
We evaluated the gene expression profiles of the cell lines before
exposure to PLX4032. Unsupervised clustering revealed two distinct
molecular groups (Figure 2A). This is consistent with others who have
also shown heterogeneity in the gene expression profiles of melanoma
samples [25–27]. An ANOVAwas performed to identify and evaluate
the individual transcriptomes of each group.
Group A is dominated by melanoma markers and genes associated
with melanin production and melanocyte function (Table W1A). We
therefore designated group A as the differentiated melanocyte group
(DMG). The gene expression profile of the DMG includes genes
upregulated through the activity of the microphthalmia-associated
transcription factor (MITF) and its downstream signaling pathway.
As an illustration, differential clustering highlights the link between
and shows the expression pattern of melanocyte-specific genes MITF,
β-catenin (CTNNB1), and cyclin-dependent kinase 2 (CDK2;
Figure 2B). CTNNB1, through activity of the canonical Wnt pathway,
is known to increase the expression of MITF [28]. CDK2 is a major
cell cycle regulator linked to melanoma growth through MITF [29].
Comparatively, group B is defined by the lack of expression of
melanocyte-specific genes. A significant decrease inMITF and β-catenin
is noted compared with the DMG (Figure 2B). Correlative changes
were noted in the activity of theWnt receptor signaling pathways, sug-
gesting activity of the noncanonical Wnt pathway in group B with
resulting inhibition of the canonical pathway [30–32]. Wingless-type
MMTV integration site family 5a (Wnt5a), upregulated in group B,
increases the motility and metastatic potential of melanoma [33,34],
and consistent with this analysis, Wnt5a has also been shown to sup-
press melanoma associated antigens such as gp100 [35].
CTNNB1 and MITF play a crucial role in melanoblast differen-
tiation from the neural crest (NC) [28,36]. The relative decreased
expression of these genes suggests that cells of group B develop along
aNC lineage distinct from typical melanocytes. Specific growth factors
have been identified that regulate NC cell (NCC) differentiation and
development. Endothelin 1, neuregulin, neurturin, and glial cell line–
derived neurotrophic factor influence the development of NCC pre-
cursors along mesenchymal and neural lineages [37]. The differential
expression of these ligands in the cell lines affords insight into their
potential developmental patterns (Figure 2B; Table W1B).
A subset of melanocytes that are produced from skin-innervating
nerve cells has been described [38]. These nerve cells develop from
Schwann cell precursors (SCPs) that retain the developmental poten-
tial to formmelanocytes. Themelanocyte-forming SCPsmigrate along
the ventral aspect of the neural tube, opposed to the melanoblast-fated
NCC that migrate from the dorsal aspect. This neuronal versus mela-
noblastic fate decision is determined by the dueling expression of
H6 family homeobox 1 (HMX1) and SRY (sex-determining region Y)-
box 10 (SOX10). HMX1 expression in the dorsal root ganglia dif-
ferentiates NCC into neuronal phenotypes. Absence of HMX1
allows the influence of SOX10 to dominate development. SOX10+
cells express MITF and develop along the well-described melanocytic
lineage [38].
We suspect that cell lines in the DMG follow typical patterns of
melanocyte development from the dorsal aspect of the neural tube.
This group is defined by the expression ofMITF, CTNNB1, and other
melanocyte specific NC mediators (endothelin receptor type B
[EDNRB] and neurturin). Cells in group B lack the relative influences
of MITF and CTNNB1 and express ligands typical of neuronal and
mesenchymal NCC development (Figure 2B and Table W1B). This
suggests that they may represent the versatility of less differentiated
progenitor/precursor cells that develop into melanocytes under strong
neuronal influences, possibly the SOX10− SCP cells. As such,melanoma
group B is designated the neuronal precursor group (NPG). The NPG
is composed of two subgroups (NPG1 and NPG2), as defined by their
respective gene expression signature.NPG2 lacks the expression of genes
that strongly differentiate the DMG from the NPG1 (Figure 2B).
Gene Expression Groupings/Response PLX4032
PLX4032 growth inhibition results were compared with the gene
expression groupings that are listed above (Figure 1A). Of the 13 cell
lines in the clearly sensitive group, 9 belong to the DMG, whereas 4
belong to the NPG (1 in NPG1 and 3 in NPG2). Of the intermediate
group, one of six cell lines is in the DMG, whereas five are in the NPG
(three in NPG1 and two NPG2). Of the 16 resistant cell lines, 4 are in
theDMGand 12 are in theNPG (8 inNPG1, 3 inNPG2, and 1N/A).
Specifically, 23 cell lines have a BRAFm (11 in DMG and 12 in NPG).
Of those in the DMG, nine are clearly sensitive, one is intermediate,
and one is resistant. Of the BRAFm cell lines in the NPG, four are
clearly sensitive (one in NPG1 and three in NPG2), five are interme-
diate (three in NPG1 and two in NPG2), and three are resistant (three
in NPG1 and none in NPG2). Taken together, these observations
suggest that melanoma cells become more dependent on downstream
transcriptional effects of BRAF mutated ERK signaling as they be-
come more differentiated, possibly because of the increased interac-
tions with MITF.
Gene Expression Profile Before/After Exposure PLX4032
An ANOVA was performed comparing PLX4032-sensitive and
-resistant cell lines. Distinct gene expression signals could not be iden-
tified apart from the patterns that define the DMG and the NPG. To
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overcome the expressional strength of each subgroup, gene expression
profiling was performed on individual samples before and after
PLX4032 exposure (Figure 2C and Table W2). Thirteen cell lines
were chosen (eight were sensitive and five were resistant; ten with a
BRAFm, two with a NRASm, and one WT; eight in DMG, two in
NPG1, and three in NPG2). Three cell lines clustered differently than
their growth inhibition patterns would have suggested. SKMEL31,
BRAFm/sensitive, had few changes in its posttreatment array; M308
and SKMEL3, BRAFm/resistant, had an expression profile more simi-
lar to the sensitive lines. The cluster pattern of these 13 cell lines is very
consistent with the patterns of p-ERK signaling that were noted on
Western analysis after exposure to PLX4032. The expression profile
of SKMEL31, sensitive, clusters with the resistant cell lines CHL1,
M207, and M202; these four cell lines show continued p-ERK sig-
naling on Western analysis after exposure to PLX4032. M308 and
SKMEL3 show loss of p-ERK despite being resistant to PLX4032.
These cell lines cluster with the seven PLX4032-sensitive cell lines,
all of which had abrogation of p-ERK signaling. These observations
suggest that the dominant genetic signatures generated by this analysis
are due to the effect/lack of effect of PLX4032 on p-ERK signaling.
To investigate the individual genes and molecular processes associ-
ated with the application of PLX4032, a function-based gene analysis
was performed on the before/after treatment data. Illustrative gene
changes are depicted (Figure 2D).
Figure 2. Gene expression analysis of the 35MM cell lines. (A) Global view of unsupervised two-dimensional clustering of the 35 cell lines
using a statistical cutoff for genes with a two-fold change in at least four experiments (3997 resulting genes). Cell lines (top), individual
genes (left). Red increased expression; green, decreased expression. Color intensity correlates with degree of expression compared with
the complementary RNA mixed reference pool. (B) Supervised clustering: differential gene expression patterns of melanoma cell lines
generated by an ANOVA. Two-dimensional clustering of 35 melanoma cell lines based on the expression pattern of selective genes
associated with MITF (A_23_P61937) and its downstream signaling pathway, melanocyte function, melanin synthesis, noncanonical
Wnt and Tgfβ pathways, and neuronal mediators of NCC development. Length of dendogram arm depicts degree of association of the
cell lines based on the expression pattern of these 37 genes. MM subgroups are represented by color blocks on the right of the cluster
diagram (blue—group A [DMG], red—group B1 [NPG1], green—group B2 [NPG2]). (C) Global clustering of eight sensitive and five resistant
cell lines after their exposure to PLX4032. Expression signatures depict the fold change of the posttreatment versus pretreatment samples.
A statistical cutoff for genes with at least a two-fold change in at least four experiments was performed, resulting in 1927 genes that had
a P < .01. (D) Two-dimensional clustering that displays the expression patterns of genes associated with aberrant ERK signaling and
melanocyte differentiation and function. Each row displays the difference in the expression of genes in the post treatment line compared
with the pretreatment line. (E) Western blot analysis of C-MYC expression in selected cell lines before and after exposure to PLX4032.
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Protein Kinase Activity
An assessment of protein kinase activity in the sensitive lines re-
vealed a significant decrease in DUSP 4, 5, and 6 and in SPRY 2
and 4. DUSPs are highly inducible cytoplasmic and nuclear phospha-
tases that negatively regulate ERK activity. SPRYs are also negative reg-
ulators of MAPK signaling with target effects above ERK. These noted
decreases support down-regulation of the MAPK pathway in BRAF
mutated cells through target inhibition with PLX4032. Similar recip-
rocal events were seen in melanoma samples treated with selective
MEK inhibitors [8,39].
Cellular Proliferation/Apoptosis
The effects of ERK signaling on cellular proliferation and apoptosis
in cancer are well described [7,40]. Activity of ERK-dependent tran-
scription factors, includingMYC, EGR1, FOSL1, IER3, and the fam-
ily of ETS variants (ETV1, ETV4, and ETV5), has been noted in
BRAF mutated MM [8]. The treatment of BRAF mutated melanoma
cells with PLX4032 caused a significant decrease in the expression of
these transcription factors. The decreased expression ofMYCwas con-
firmed on the protein level (Figure 2E ). Significant changes were
noted in the downstream effectors of these factors including a decrease
in selective markers of cellular proliferation (CCND1 and CDK6) and
an increase in several BH3 domain-containing proapoptotic factors
(BMF and PUMA/BBC3; Figure 2D).
Differentiation/Functional Genes
An interesting phenomenon noted with the application of selective
MEK inhibitors in melanoma is an increase in markers of melanocyte
differentiation. This was originally described with tyrosinase (TYR)
and EDNRB [39,41]. TYR is an enzyme necessary for the conversion
of tyrosine to melanin; EDNRB is a receptor for endothelin, a ligand
that is essential for melanocyte development and the transcription of
MITF. TYR and EDNRB were preferentially expressed in the DMG.
Because of this observation, the significant disparity in the expression
of melanocyte differentiation markers between the DMG and NPG,
and the preferential response of the DMG to BRAF inhibition, we ex-
amined the patterns of differentiation that occur after exposure to
PLX4032 (Figure 2D). PLX4032 caused an increase in the expression
of melanocyte-specific genes in sensitive cell lines of both the DMG
and NPG. Significant changes were seen in TYR, TYRP1, EDNRB,
MLANA, DCT, and MITF. Genes associated with melanosome func-
tion, RAB27A, MYO5, MLPH, and RILP, were also upregulated. It
seems that a BRAFm causes a differentiation arrest that inhibits typical
melanocyte function as pertaining to melanin synthesis and transport.
Prolonged p-ERK signaling has been shown to be a negative regulator
of melanogenesis [42]. This prevents the overproduction of lethal
amounts of melanin. The inhibition of aberrant ERK signaling may
relieve the negative feedback inhibition on melanogenesis and explain
why an increase in differentiation markers specific to melanin produc-
tion and transport is noted after treatment with PLX4032.
Acquired PLX4032 Resistance
Six BRAFm/PLX4032–sensitive cell lines (M288, SKMEL28, M14,
WM2664, COLO829, andM238) were grown in increasing concentra-
tions of PLX4032. Three have acquired resistance (M288R, SKMEL28R,
and M14R). The growth rate of these cell lines is, to a variable degree,
dependent on the continued presence of PLX4032 (Figure 3A). Growth
of M288R, PTEN null, seems fully dependent on the presence of
PLX4032. This cell line did not grow in the absence of PLX4032 and
remained quiescent until the starved serum was resupplemented with
drug (Figure 3A). SKMEL28R and M14R grew slower in the absence
of PLX4032; however, these cells were able to overcome their lag phase
and enter a growth phase that was less than, but parallel to, the growth of
the cell line that was maintained in the continued presence of drug. This
is depicted in the growth assay of SKMEL28R (Figure 3A).
Of the six cell lines grown in the constant presence of PLX4032,
M288, SKMEL28, and M14 have, whereas WM2664, COLO829,
and M238 have not yet, acquired resistance. M288, SKMEL28, and
M14 are all in the DMG. This is opposed to WM2664, COLO829,
and M238 who are all in the NPG2. This suggests that, although cell
lines of the DMG show a preferential response to PLX4032, their re-
sponse may be more transient. Such an observation may provide, by
evaluating genes specific to the DMG, molecular biomarkers that
could be used clinically to identify patients who are at high risk for
developing early PLX4032 resistance.
Resistance was confirmed with growth inhibition assays, lack of a
cell cycle arrest, and absence of apoptosis (Figure 3, B–D). Western
blot analysis shows that p-ERK signaling was maintained after ex-
posure to PLX4032 in M288R, SK-MEL-28R, and, to a lesser degree,
M14R (Figure 3E ). These data suggest that acquired resistance devel-
ops in part by reestablishingMAPK signaling. The fact that only a par-
tial restoration of p-ERK signaling was noted in M14R suggests that
the acquisition of resistance may be multifactorial and mediated by
pathways other than theMAPK. Evaluation of ARAF, BRAF, and CRAF
signaling in SKMEL28R, M14R, and M288R did not show an increase
in the phosphosignaling of these mediators compared with their parental
counterparts (Figure 3E).
MEK signaling was also evaluated in the sensitive/resistant pairs
(Figure 3E ). p-MEK signaling was not as strong in SKMEL28R,
M14R, and M288R compared with SKMEL28, M14, and M288.
As expected, treatment with PLX4032 abrogated p-MEK signaling
in SKMEL28, M14, and M288; however, p-MEK signaling was only
partially reestablished in the resistant counterparts. The intensity of
p-MEK did not correlate with the brisk p-ERK signal that was noted
in SKMEL28R and M288R after exposure to PLX4032. This suggests
that mediators other than RAF/MEK may activate ERK in the cell
lines with acquired PLX4032 resistance.
RAS status was also evaluated in the three cell lines with acquired
resistance. Exon 2 of NRAS was sequenced. As expected, sequences in
M288R, SKMEL28R, M14R were identical to their sensitive parental
cell lines (data not shown). As numerous additional mechanisms
exist, which could cause RAS activation, we performed a RAS assay
(Figure 3F ). M288R and, to a lesser degree, SKMEL28R and M14R
had an increase in RAS-GTP levels compared with their parental coun-
terparts. These data suggest that RAS activity is upregulated in BRAFm
MM samples that acquire resistance to PLX4032.
Evaluation of the AKT/mTOR pathway was also performed. Subtle
increases in p-AKT were noted in SKMEL28R and M288R (PTEN
null) but not in M14 (Figure 3E). The amount of total AKT seemed
to be less in SKMEL28R,M14R, andM288R compared with SKMEL28,
M14, and M288. Evaluation of the three AKT isoforms suggests that
this is, in part, explained by decreasing levels of AKT 3.
M14, M288, and SKMEL28 (sensitive and resistant) were exposed
to RAD001, an mTOR inhibitor, and to LY294002, a PI3K inhibitor.
Both RAD001 and LY294002 had minimal effect as a single agent on
SKMEL28 (IC50g 12 and 8 μM, respectively) andM14 (15 and 7 μM)
or SKMEL28R (11 and 7 μM) and M14R (14 and 5 μM). M288
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Figure 3. Analysis of resistant cell lines (M288R, SK-MEL-28R, and M14R) compared with their sensitive parental counterparts (M288,
SK-MEL-28, and M14). (A) Growth curves of SKMEL28Rand M288R. Blue lines—cells grown in the continued presence of PLX4032, pink—
absence of PLX4032, yellow—grown in the absence and then the presence of PLX4032; y-axis—cell count, x-axis—day of count. (B) Growth
inhibition assay (IC50g μM) in the presence of PLX4032. (C) Cell cycle and (D) apoptosis assays as done by flow cytometry. (E) Phosphoprotein
signaling of MM cell lines before and after exposure to PLX4032. Two separate total AKT antibodies that recognize different epitopes were
used. (F) RAS activation assay in sensitive and resistant counterparts before and after exposure to PLX4032. (G) A comparative gene expres-
sion analysis of the expression profiles ofM288R, SKMEL28R, andM14R andM14,M288, and SKMEL28. Selected genes are listed. Columns
depict fold change in the gene expression ofM288R, SKMEL28R, andM14R comparedwithM14,M288, and SKMEL28 and the fold change
in the gene expression in the post PLX4032 treatment samples of M14, SKMEL28, and M288 compared with pretreatment controls.
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was resistant to LY294002 (IC50g 7 μM) and relatively resistant to
RAD001 (IC50g 3 μM). Comparatively, M288
R was more sensitive
to both RAD001 and LY294002 (IC50g 1 and 2 μM, respectively).
However, the number of generations observed inM288R in the growth
inhibition assay was limited because the single-agent assays were done in
the absence of PLX4032. In M288R, the combination of RAD001 and
PLX4032 or LY294002 and PLX4032 did not improve the response
to either drug alone (data not shown). Overall, these data do not offer
strong support for the PI3K pathway contributing to the growth and
survival of BRAFm MM cell lines that acquired PLX4032 resistance.
Because of the rapidity in which resistance developed, we favor
the reestablishment of MAPK signaling, the activation of feedback
mechanisms, and/or epigenetic modifications rather than secondary
point mutations that prevent PLX4032 from interacting with the
mutated BRAF. We sequenced the G loop and the activation do-
main, exons 11 and 15, respectively, of the BRAF kinase. Sequences
in M288R, SKMEL28R, and M14R were identical to their sensitive
parental cell lines (data not shown). This suggests that resistance does
not occur through a change in ATP binding or phosphorylation capacity.
A gene expression analysis was conducted comparing M288R,
SKMEL28R, and M14R to M14, M288, and SKMEL28 at baseline
and after the parental strains were treated with PLX4032 (Figure 3G
and Table W3). Such an analysis reveals the genetic changes that a cell
undergoes as it acquires drug resistance and how resistance affects the
expression signature that is generated by PLX4032.
The expression profile of M288R, SKMEL28R, and M14R revealed
variable changes in the expression patterns of DUSP 4, 5, and 6 and
SPRY 2 and 4, the nuclear transcription factors MYC, EGR1, FOSL1,
IER3, ETV1, ETV4, and ETV5 as well as certain melanocytic genes
(DCT, RAB27A, MLANA, and SILV ). Genes that defined the NPG
such as wnt5A, neuregulin, endothelin 1, DKK1, INHBB, AXL, and
CYR61 were upregulated to variable degrees in M288R, SKMEL28R,
and M14R compared with their parental counterparts. It seems that
although MAPK signaling is reestablished when resistance develops,
it is not specifically driven by a BRAFm because the characteristic
gene expression signature of a BRAFm was not encountered. This is
in accordance with the patterns of RAS activity and p-ERK/p-MEK
signaling that was noticed in the cell lines with acquired resistance.
In addition, M288R, SKMEL28R, and M14R belong to the DMG.
The fact that an NPG expression signature is encountered in cells of
the DMG suggests that the expression signature of the NPG repre-
sents a more primordial/default signature that develops in the absence
of melanocytic differentiation or differentiation signals.
Finally, numerous genes were upregulated in M288R, SKMEL28R,
and M14R compared to M14, M288, and SKMEL28 (Figure 3G and
Table W3). This included platelet-derived growth factor A and cer-
tain mediators of angiogenesis (interleukin 8, VEGFC ). Significant
increases were also noted in the expression of certain metallothioneins
(MTs). MTs are low-molecular weight cysteine-rich proteins that func-
tion in intracellular metal metabolism/detoxification. A role for these
proteins is emerging in cancer, including melanoma in which their
expression is an independent prognostic variable [43]. MTs also have
antiapoptotic activity and are implicated in metal- and nonmetal-
containing cytostatic drugs’ resistance [44,45].
The increased expression of these mediators in PLX4032-acquired
resistance suggests the activity of additional survival pathways that may
be amenable to targeted therapy either in rescue of or in combination
with BRAF inhibition. Also, genes such as interleukin 8 or the MTs
may be useful biomarkers that signal when resistance is about to de-
velop in patients undergoing treatment with PLX4032.
Figure 3. (continued).
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Discussion
MM, once thought to be a single entity, is now considered a molecular
and developmentally diverse disease. This observation allows for the
generation and application of novel therapies specifically targeted to
the molecular pathway lesions of a patient’s disease. Such an approach
affords the opportunity to positively affect the historically low survival
rates in melanoma and serves as a molecular tool to help dissect the
oncogenic events that drive this disease.
The effect of aberrant ERK signaling in MM is well described [7].
Consequently, the clinical application of selective MAPK inhibitors is
currently underway. PLX4032 is a potent inhibitor of the mutated
form of BRAF. An early phase 1 trial of this compound in MM has
been promising [14]. However, concurrent preclinical molecular re-
search is required to supplement clinical findings and to help direct
the proper clinical application of PLX4032, including how to predict
and overcome the development of drug resistance.
We tested the efficacy of PLX4032 in a large panel of well-
characterized MM cell lines. The presence of BRAFm predicted for,
but did not guarantee, a response to therapy. In addition to a BRAFm,
samples that had a concurrent MC1Rv and a more differentiated mel-
anocytic genotype had a preferential response. This provides valuable
information that could be used to screen and select future clinical trial
participants and to retrospectively analyze tissue and outcome results
from the completed phase 1 trial.
Phosphoprofiling of our samples before and after PLX4032 treat-
ment confirmed the inhibition of p-ERK signaling in all cell lines with
a BRAFm regardless of response. This confirms the specificity of
PLX4032 and the dependency of most BRAFm MM cells on p-ERK
signaling. SKMEL31, sensitive, was an exception to this. After expo-
sure to PLX4032, SKMEL31 had an increase in p-ERK signaling, much
like NRAS mutated or BRAFwt/NRASwt samples. It is possible that
SKMEL31 has a reverse mutant allele-specific imbalance in which the
wild-type allele is increased compared to the mutant [24]. The presence
of the mutated allele must be sufficient to drive its malignant phenotype
and confer sensitivity to PLX4032. However, the imbalance in favor of
the wild-type allele could explain why its post-PLX4032 p-ERK signal-
ing pattern is more consistent with a BRAFwt cell line. Of the 23 MM
cell lines with a BRAFm, 15 are heterozygous. Evaluation of the chro-
matogram of these cell lines revealed SKMEL31 and SKMEL3 as the
only two lines that have a higher peak of the wild-type allele compared
with the mutant. Interestingly, SKMEL3 is the most resistant cell line
in the panel. It is possible that this reverse allelic imbalance will explain
the phosphosignaling pattern of SKMEL31 and provide a way to predict
resistance in patients who are heterozygous for the BRAFm.
Abrogation ofMAPK signaling in the PLX4032-resistant BRAFm cell
lines suggests that a small population of MM samples exist that have
aberrant ERK signaling but can survive in the absence of this path-
way’s functional input. These samples (BRAFm PLX4032-resistant)
were heterozygous for the BRAFm, tended to be in the NPG, and were
without a MC1Rv. Further validation of the unique qualities of this
population may identify alternate signaling pathways, treatment op-
tions, and those patients with a BRAFm who would not benefit from
single-agent RAF inhibition. Also, our analysis clearly suggests that
patients with NRASm or NRASwt/BRAFwt tumors would not benefit
from PLX4032. As expected, the application of PLX4032 in these
cells did not abrogate p-ERK signaling. Instead, selective BRAF inhi-
bition seemed to activate the MAPK pathway as previously described
[46,47]. A correlation in response to PLX4032 was noted in the BRAF
mutated samples that have a concurrent MC1R polymorphism.
Figure 3. (continued).
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BRAFm/MC1R normal cell lines were resistant to the effects of
PLX4032. This suggests that melanoma cells that have BRAFm/MC1Rv
are more dependent on aberrant p-ERK signaling as driven by the
BRAFm. The dominant effect of both pathways may converge onMITF
signaling. This may explain why cell lines in the DMG that are BRAFm/
MC1Rv seem to be more sensitive to PLX4032 than cell lines in the
NPG that are BRAFm/MC1Rv.
The application of PLX4032 in the MM cell lines shows the down-
stream effect of ERK signaling in BRAF mutated samples. We per-
formed cell cycle and apoptotic analyses before/after exposure to the
drug. Interruption of ERK signaling decreased cellular proliferation
and the ability to escape apoptosis. Our gene expression data suggest
that BMF and PUMA mediate the restoration of apoptosis. Our ex-
pression analysis also confirmed that MAPK activity in BRAFmutated
MM is resistant to negative feedback inhibition of DUSP and SPRY
and that MYC, FOSL1, EGR1, and ETV 1, 4, and 5 are the main
transcriptional activators of ERK as driven by a BRAFm.
An interesting observation noted with the disruption of ERK signal-
ing is the reexpression of melanocyte-specific genes and markers of
melanocyte differentiation. This includes TYR, MLANA, DCT, and
MITF. It is uncertain why these differentiation markers are decreased
in MM by ERK signaling. However, it has been suggested that pro-
longed ERK signaling will decrease the expression of MITF with sub-
sequent down-regulation of melanogenesis to avoid the cytotoxic
effects of excess melanin production [42]. Consistent with this is our
observation that genes associated with melanosome function, RAB27A,
MYO5,MLPH, and RILP, were reexpressed after MM cell lines with a
BRAFm were treated with PLX4032. The inhibition of aberrant ERK
signaling in BRAF mutated samples, especially ones that have a
MC1Rv, may relieve the feedback inhibition of ERK and reestablish
the innate drive for melanin production.
Adding to the complexity of the relationship between ERK signal-
ing and melanocyte differentiation is the identification of a subset of
melanoma samples whose genotype is more characteristic of neuronal
precursors than that of typical melanocytes. These cells behave and
function like melanocytes, develop into clinically indistinguishable
melanomas, and are susceptible to common melanoma mutations.
However, they have very distinct gene expression signatures that sug-
gest activity of the noncanonical Wnt and TGFβ pathways at the
expense of MITF, CTNNB1, and the canonical Wnt pathway. Inter-
estingly, BRAF mutated MM samples of the NPG have an increase in
melanocytic genes after PLX4032 exposure. Also, BRAFmutatedMM
cell lines of the DMG that develop resistance to PLX4032 have an in-
crease in the expression of genes that are more characteristic of cells
with in the NPG. These data suggest that plasticity does exist between
the DMG and NPG and that cell lines of the NPG may be able to
differentiate into a more melanocytic phenotype if they encounter
the proper internal/external cues.
Our data show that the cells of DMGweremore dependent on ERK
signaling when driven by a BRAFm. Cell lines of the DMG were more
sensitive to PLX4032 than were BRAFm cells in the NPG. Interestingly,
those cell lines in the NPG that were clearly sensitive to PLX4032 were
mostly in the NPG2, the group that was not defined by melanocytic or
by neuronal genes. It is possible that this group represents a genetic
bridge that links the DMG with the NPG1 and the plasticity inherent
to NCC development.
We propose that cells of the NPG develop from the NC apart from
the influence of SOX10 and MITF. In such, they never develop a strong
melanocytic genotype and retain much of the neuronal influences of their
precursors. A higher incidence of PTEN loss was noted in these cells.
PTEN loss has been shown in conjunction with a BRAFm to facilitate
melanoma development [10,11]. We noticed a predilection of the
PTENm to be in the NPG regardless of BRAF status. This suggests that
the less differentiated cells of the NPGmay be more dependent on the
cross talk between the MAPK and PI3K pathways that is thought to
potentiate melanoma formation in BRAF mutated nevi.
As seen clinically, continual exposure of melanoma to PLX4032 can
promote drug resistance especially in the more differentiated samples.
Western blot analysis showed reactivation of p-ERK signaling. However,
a gene expression analysis did not consistently reproduce the downstream
signaling patterns of a fully penetrable BRAFm. These data suggest that
other mediators may contribute to the acquisition of resistance. In the
samples with PLX4032 acquired resistance, we noticed increase activity
of RAS and a discordant signaling pattern betweenMEK and ERK. This
may afford some insights into points of influence on MAPK pathway
apart from a BRAFm. Changes in AKTand p-AKTsignaling were noted
in the resistant samples compared with their sensitive parental counter-
parts. However, further assessment, including treatment data with selec-
tive PI3K andmTOR inhibitors, did not make a strong argument for this
pathways involvement in acquired PLX4032 resistance.
A gene expression analysis implicated several other mediators that
may be involved in the acquisition of resistance to PLX4032; this in-
cludes members of the platelet derived growth factor family, increased
expression of angiogenic factors, and increased activity of certain MTs.
Such observations afford biomarkers to screen for the development of
resistance in patients who are actively being treated with PLX4032 and
possible clinical avenues to pursue when resistance occurs.
PLX4032 is a selective BRAF inhibitor that seems to have signifi-
cant clinical activity in BRAF mutated MM. The development of this
compound provides hope in a malignancy that has been notoriously
refractory to standard therapies. The preclinical use of this molecule
sheds light onto its proper clinical application and affords new insight
into patterns of response and resistance. Such information furthers our
understanding of this terrible malignancy and opens the door to new
targeted therapies and the clinical means to properly apply them in the
context of well-defined pathway lesions.
Acknowledgments
The authors thank UCLA Sequencing Core and Jim Economou and
Antoni Ribas for providing the cell lines that were developed at UCLA.
References
[1] Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH,
Aiba S, Brocker EB, LeBoit PE, et al. (2005). Distinct sets of genetic alterations
in melanoma. N Engl J Med 353, 2135–2147.
[2] Curtin JA, Busam K, Pinkel D, and Bastian BC (2006). Somatic activation of
KIT in distinct subtypes of melanoma. J Clin Oncol 24, 4340–4346.
[3] Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D,
Kanetsky PA, Pinkel D, and Bastian BC (2006). MC1R germline variants confer
risk for BRAF-mutant melanoma. Science 313, 521–522.
[4] Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH,
Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, et al. (2008). Phase II trial
of imatinib mesylate in patients withmetastatic melanoma. Br J Cancer 99, 734–740.
[5] Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K,
Carberry M, Troxel AB, Letrero R, Nathanson KL, et al. (2009). Phase II trial of
temozolomide and sorafenib in advanced melanoma patients with or without
brain metastases. Clin Cancer Res 15, 7711–7718.
[6] Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G,
Cerimele F, Govindarajan B,Macaron N, and Arbiser JL (2002). Mitogen-activated
protein kinase activation is an early event in melanoma progression. Clin Cancer Res
8, 3728–3733.
648 BRAF Inhibition with PLX4032 in Malignant Melanoma Tap et al. Neoplasia Vol. 12, No. 8, 2010
[7] Gray-Schopfer V, Wellbrock C, and Marais R (2007). Melanoma biology and
new targeted therapy. Nature 445, 851–857.
[8] Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, and Rosen N (2009).
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK
signaling and elevated transcriptional output of the pathway. Proc Natl Acad
Sci USA 106, 4519–4524.
[9] Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, and
Robbins JB (2007). Expression of activated Akt in benign nevi, Spitz nevi
and melanomas. J Cutan Pathol 34, 593–596.
[10] Cheung M, Sharma A, Madhunapantula SV, and Robertson GP (2008). Akt3
and mutant V600E B-Raf cooperate to promote early melanoma development.
Cancer Res 68, 3429–3439.
[11] Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr,
You MJ, DePinho RA, McMahon M, and Bosenberg M (2009). Braf(V600E)
cooperates with Pten loss to induce metastatic melanoma.Nat Genet 41, 544–552.
[12] Gray-Schopfer VC, Karasarides M, Hayward R, and Marais R (2007). Tumor
necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is
inhibited. Cancer Res 67, 122–129.
[13] Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, and Gambacorti-Passerini
C (2008). BRAF silencing by short hairpin RNA or chemical blockade by
PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Mol Cancer Res 6, 751–759.
[14] Chapman P, Puzanov I, Sosman J, Kim KB, Ribas A, McArthur G, Lee R, Grippo
J, Nolop K, and Flaherty K (2009). Early efficacy signal demonstrated in advanced
melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032.
Eur J Cancer 7(suppl 3), 5.
[15] Sondak VK and Smalley K (2009). Targeting mutant BRAF and KIT in meta-
static melanoma: ASCO 2009 meeting report. Pigment Cell Melanoma Res 22,
386–387.
[16] Finn RS, Dering J, ConklinD, KalousO, CohenDJ, Desai AJ, Ginther C, AtefiM,
Chen I, Fowst C, et al. (2009). PD 0332991, a selective cyclin D kinase 4/6
inhibitor, preferentially inhibits proliferation of luminal estrogen receptor–
positive human breast cancer cell lines in vitro. Breast Cancer Res 11, R77.
[17] Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek
A, Potter DA, Woo RA, O’Rourke DM, et al. (2008). Gene silencing for epi-
dermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol
Cancer Ther 7, 3586–3597.
[18] Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe DJ,
Golubeva Y, Calista D, Seidenari S, Massi D, et al. (2008). MC1R variants
increase risk of melanomas harboring BRAF mutations. J Invest Dermatol
128, 2485–2490.
[19] Tsao H, Goel V, Wu H, Yang G, and Haluska FG (2004). Genetic interaction
between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in mel-
anoma. J Invest Dermatol 122, 337–341.
[20] Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM,
She Y, Osman I, et al. (2006). BRAF mutation predicts sensitivity to MEK in-
hibition. Nature 439, 358–362.
[21] Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, and Frankel AE
(2005). BRAF status andmitogen-activated protein/extracellular signal–regulated
kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal
toxin. Mol Cancer Ther 4, 1303–1310.
[22] Christensen C and Guldberg P (2005). Growth factors rescue cutaneous
melanoma cells from apoptosis induced by knockdown of mutated (V 600 E)
B-RAF. Oncogene 24, 6292–6302.
[23] Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, and
Shields JM (2007). Context-dependent roles of mutant B-Raf signaling in mel-
anoma and colorectal carcinoma cell growth. Mol Cancer Ther 6, 2220–2229.
[24] Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W,
Chari R, Shames DS, Tang X, MacAulay C, et al. (2009). Oncogene mutations,
copy number gains and mutant allele specific imbalance (MASI) frequently
occur together in tumor cells. PLoS One 4, e7464.
[25] Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M,
Simon R, Yakhini Z, Ben-Dor A, et al. (2000).Molecular classification of cutaneous
malignant melanoma by gene expression profiling. Nature 406, 536–540.
[26] Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H,
Penland S, Arbiser J, Scott G, et al. (2007). Lack of extracellular signal–regulated
kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Cancer Res 67, 1502–1512.
[27] Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL,
Nathanson KL, Phillips DJ, Herlyn M, et al. (2006). Metastatic potential of
melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res 19, 290–302.
[28] Schepsky A, Bruser K, Gunnarsson GJ, Goodall J, Hallsson JH, Goding CR,
SteingrimssonE, andHechtA (2006). Themicrophthalmia-associated transcription
factor Mitf interacts with β-catenin to determine target gene expression. Mol Cell
Biol 26, 8914–8927.
[29] Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE,
Nishimura EK, Golub TR, and Fisher DE (2004). Critical role of CDK2 for
melanoma growth linked to its melanocyte-specific transcriptional regulation by
MITF. Cancer Cell 6, 565–576.
[30] Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, and Yang Y (2003).
Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent
β-catenin degradation. J Cell Biol 162, 899–908.
[31] Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH,
and Aaronson SA (1999). Isolation and biochemical characterization of the hu-
man Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol
Chem 274, 19465–19472.
[32] Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S,
Aaronson SA, Varmus HE, and Rubin JS (1997). Purification and molecular
cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad
Sci USA 94, 6770–6775.
[33] Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, and
Trent JM (2002). Wnt5a signaling directly affects cell motility and invasion of
metastatic melanoma. Cancer Cell 1, 279–288.
[34] O’Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD,
Dissanayake SK, Indig FE, Bernier M, et al. (2010). The orphan tyrosine kinase
receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene
29(1), 34–44.
[35] Dissanayake SK, Olkhanud PB, O’Connell MP, Carter A, French AD, Camilli TC,
Emeche CD, Hewitt KJ, Rosenthal DT, Leotlela PD, et al. (2008). Wnt5A regu-
lates expression of tumor-associated antigens in melanoma via changes in signal
transducers and activators of transcription 3 phosphorylation. Cancer Res 68,
10205–10214.
[36] Larue L, Kumasaka M, and Goding CR (2003). β-Catenin in the melanocyte
lineage. Pigment Cell Res 16, 312–317.
[37] Martinez-Morales JR, Henrich T, RamialisonM, andWittbrodt J (2007). New genes
in the evolution of the neural crest differentiation program. Genome Biol 8, R36.
[38] Adameyko I, Lallemend F, Aquino JB, Pereira JA, Topilko P, Muller T, Fritz N,
Beljajeva A, Mochii M, Liste I, et al. (2009). Schwann cell precursors from nerve
innervation are a cellular origin of melanocytes in skin. Cell 139, 366–379.
[39] Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi
MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al. (2009). Growth-
inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in ma-
lignant melanoma with or without BRAF mutations. Neoplasia 11, 720–731.
[40] Gray-Schopfer VC, da Rocha Dias S, and Marais R (2005). The role of B-RAF
in melanoma. Cancer Metastasis Rev 24, 165–183.
[41] Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-
Leopold J, Larson S, and Rosen N (2007). 3′-Deoxy-3′-[18F]fluorothymidine
positron emission tomography is a sensitive method for imaging the response of
BRAF-dependent tumors to MEK inhibition. Cancer Res 67, 11463–11469.
[42] KhaledM, Larribere L, Bille K, AberdamE,Ortonne JP, Ballotti R, and Bertolotto
C (2002). Glycogen synthase kinase 3β is activated by cAMP and plays an active
role in the regulation of melanogenesis. J Biol Chem 277, 33690–33697.
[43] Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, and Zelger B (2006).
Metallothionein—overexpression as a highly significant prognostic factor in
melanoma: a prospective study on 1270 patients. Br J Cancer 94, 835–841.
[44] Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, Hayasaka A,
Kondo F, Sugiura N, and Saisho H (2004). Immunohistochemical metallothio-
nein expression in hepatocellular carcinoma: relation to tumor progression and
chemoresistance to platinum agents. J Gastroenterol 39, 1196–1201.
[45] Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, and
Waalkes MP (2003). Metallothionein is a potential negative regulator of apop-
tosis. Toxicol Sci 73, 294–300.
[46] Poulikakos PI, Zhang C, Bollag G, Shokat KM, and Rosen N (2010). RAF
inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type
BRAF. Nature 464(7287), 427–430.
[47] Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R,
Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. (2010). RAF inhibitors prime
wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464
(7287), 431–435.
Neoplasia Vol. 12, No. 8, 2010 BRAF Inhibition with PLX4032 in Malignant Melanoma Tap et al. 649
Supplemental Material
Primer Sets Used in Polymerase Chain Reaction and
Sequencing Experiments for BRAF, NRAS, MC1R, PTEN,
and PI3K
